| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05823480 Details | 2024-01-02 Interventional | 1 | - | Azacitidine Magrolimab Myelodysplastic… Acute Myeloid L… Myelodysplastic… | FDA Clinical Hold - | |||
| NCT02661464 NCT02967003 2015-004139-11 Details | 2024-01-02 Interventional | 3 | 677 | Smallpox and mo… Hemorrhagic Fev… Hemorrhagic Fev… | Due to the pandemic with only one participant in follow up, as the impact on the safety was
determined to be negligible, the study was terminated early. As none of the participants met Cohort 2 eligibility criteria pre-specified in the protocol, therefore no participants were enrolled in Cohort 2. So the results were only presented for Cohorts 1 and 3. | |||
| NCT05743270 Details | 2023-12-29 Interventional | 2 | 0 | Carboplatin Nivolumab Paclitaxel Carcinoma Carcinoma, Squa… Recurrence Squamous Cell C… Locally Advance… Recurrent Head … | Sponsor decision. - | |||
| NCT05446129 Details | 2023-12-29 Interventional | 1 | 2 | Pembrolizumab Colorectal Neop… Colorectal Canc… | Company decision - | |||
| NCT05381363 Details | 2023-12-29 Interventional | 1/2 | 24 | Interferons COVID-19 Children | The study was concluded as planned upon reaching its predetermined endpoint, which included the
completion of data collection and achievement of the necessary sample size for statistical
significance. - | |||
| NCT04931511 Details | 2023-12-29 Interventional | 4 | 20 | Betamethasone Betamethasone V… Betamethasone b… Betamethasone s… Betamethasone-1… Bursitis Shoulder Pain Frozen Shoulder | Since the COVID-19 pendemic, the regular follow-up of participant became very hard. The
participant were not willing to go back to the hospital for repeat measurement. So we stop the
study and plan to redesign the protocol. - | |||
| NCT04738318 Details | 2023-12-29 Interventional | 4 | 3 | Dexamethasone Glucocorticoids Methylprednisol… Elbow Fractures Fractures, Bone Intra-Articular… Elbow Fracture | Switched to observational study type. The study was terminated early and converted to a non-interventional, observational study model. Of the 3 participants consented prior to termination, only 2 were randomized to a treatment arm and only 1 completed study procedures. | |||
| NCT04244552 Details | 2023-12-29 Interventional | 1 | 87 | Doxorubicin Liposomal doxor… Pembrolizumab Breast Neoplasm… Carcinoma Carcinoma, Ovar… Carcinoma, Squa… Colorectal Neop… Esophageal Squa… Melanoma Ovarian Neoplas… Squamous Cell C… Triple Negative… Acral Lentigino… Breast Cancer Colorectal Canc… DMMR Colorectal… Head and Neck S… Hepatocellular … MSI-H Colorecta… Non-Small Cell … Ovarian Cancer Platinum-Resist… Platinum-Resist… Platinum-Resist… Triple Negative… Urothelial Carc… | Sponsor Decision - | |||
| NCT02550028 NCT02602015 Details | 2023-12-29 Interventional | 1/2 | 60 | Levetiracetam Phenobarbital Seizures Neonatal Seizur… | The study was concluded as planned upon reaching its predetermined endpoint, which included the
completion of data collection and achievement of the necessary sample size for statistical
significance. - | |||
| NCT04641975 2016-001767-37 Details | 2023-12-28 Interventional | 3 | 26 | Mirabegron Urinary Bladder… Overactive Blad… Pharmacokinetic… | Termination due to operational futility - | |||
| NCT04756505 Details | 2023-12-27 Interventional | 1 | 0 | Immunoglobulin … Interleukin-12 Adenocarcinoma Breast Neoplasm… Anatomic Stage … Hormone Recepto… Metastatic Brea… Metastatic HER2… Prognostic Stag… | Per Sponsor Request-no longer manufacturing the study drug - | |||
| NCT04187872 Details | 2023-12-27 Interventional | 1 | 10 | Pembrolizumab Brain Neoplasms Carcinoma Carcinoma, Merk… Carcinoma, Non-… Carcinoma, Squa… Lymphoma Microsatellite … Neoplasm Metast… Neoplasms, Squa… Small Cell Lung… Brain Metastase… Cervical Cancer Classical Hodgk… Esophageal Canc… Gastric Cancer Head and Neck S… Hepatocellular … Melanoma Merkel Cell Car… Microsatellite … Non-small Cell … Primary Mediast… Renal Cell Carc… Small-cell Lung… Urothelial Carc… | Sponsor terminated - | |||
| NCT05671653 Details | 2023-12-26 Interventional | 1 | 32 | Semaglutide Obesity | The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data
from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated
transaminases in these Phase 1 studies as well as a Phase 2 study. - | |||
| NCT05514912 Details | 2023-12-26 Interventional | 2 | 0 | Albumin-Bound P… Cisplatin Gemcitabine Infigratinib Paclitaxel Cholangiocarcin… Resectable Intr… Stage 0 Intrahe… Stage I Intrahe… Stage II Intrah… Stage III Intra… | PI has decided to terminate this study due to study supporter pulling support on this study. - | |||
| NCT04912856 2020-003447-28 Details | 2023-12-26 Interventional | 3 | 8 | Ezogabine Brain Diseases Central Nervous… Epilepsy Epileptic Syndr… Nervous System … Seizures Disease Epilepsy in Chi… Epilepsy; Seizu… | Sponsor decision; not a safety decision - | |||
| NCT04492722 2020-002263-54 Details | 2023-12-26 Interventional | 2 | 613 | Dapagliflozin Kidney Diseases Renal Insuffici… Chronic Kidney … | The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety
concerns related to the study. Following study termination and reduced scope of the analysis, the PK analysis has not been performed. | |||
| NCT04065841 2019-002324-32 Details | 2023-12-26 Interventional | 2 | 234 | Licogliflozin Fatty Liver Liver Cirrhosis Non-alcoholic F… Non Alcoholic S… | The sponsor made a business decision to stop development of the trial drugs. The decision to
stop the trial early was not because of any safety concerns. - | |||
| NCT03912831 Details | 2023-12-26 Interventional | 1 | [1 Refs] | 8 | Cyclophosphamid… Fludarabine Interleukin-2 Human Papilloma… | Development program terminated - | ||
| NCT00089245 Details | 2023-12-26 Interventional | 1 | 177 | Cadexomer iodin… Iodine Central Nervous… Nervous System … Neuroblastoma Sarcoma Brain and Centr… | Corporate business decision. No safety or efficacy concerns. - | |||
| NCT05505214 Details | 2023-12-22 Interventional | 2 | 0 | Mometasone Furo… Dermatitis Radiodermatitis Radiation Derma… | Study planned but never formally submitted to the IRB - |